Soligenix with ticker code (SNGX) now have 5 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 15 and 2 and has a mean target at 6.45. With the stocks previous close at 2.74 this now indicates there is a potential upside of 135.4%. There is a 50 day moving average of 2.12 and the 200 moving average now moves to 2.01. The market capitalisation for the company is $41m. Visit the company website at: http://www.soligenix.com
Soligenix, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which is in Phase 1/2 clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn’s disease and acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; and ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines. The company was formerly known as DOR BioPharma and changed its name to Soligenix in 2009. Soligenix was incorporated in 1987 and is headquartered in Princeton, New Jersey.